Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

PJ Online | News: Thrombolytics safe for ambulance use

Home > PJ (current issue) > News / Daily News | Search

Return to PJ Online Home Page

The Pharmaceutical Journal
Vol 269 No 7226 p772
30 November 2002

This article

News summary

Thrombolytics safe for ambulance use

A combination of tenecteplase (Metalyse) and unfractionated heparin can be given safely in ambulances, a new trial has shown.

Although the efficacy of these agents has been established, the feasibility of giving antithrombotic regimens before patients have been admitted to hospital has not been demonstrated in a multicentre randomised trial until now. The trial also assessed the use of tenecteplase plus enoxaparin (Clexane) and showed that this combination reduced ischaemic events that occur in hospital. However, it was associated with an increased risk of major bleeding and intracranial haemorrhage compared with tenecteplase plus heparin.

Professor Lars Wallentin, Uppsala University, Sweden, who presented the trial data at the American Heart Association scientific sessions in Chicago last week, said: "There were advantages and disadvantages with the [enoxaparin plus tenecteplase] combination in the ambulance."

The incidence of intracranial haemorrhage increased from 0.97 per cent in patients treated with UFH to 2.2 per cent in patients treated with enoxaparin (P=0.047). "However, these were patients entirely above 75 years of age and almost entirely women," he added.

Professor Wallentin concluded that administration of thrombolytic agents in the ambulance shortens treatment delay but added that further dose finding studies in the elderly and in women were needed for the combination of enoxaparin and tenecteplase.

The National Institute for Clinical Excellence issued guidance on the use of thrombolytic agents in the pre-hospital setting in October (PJ, 2 November, p633).

Back to Top

Home | Journals | News | Notice-board | Search | Jobs  Classifieds | Site Map | Contact us

©The Pharmaceutical Journal

Citation: The Pharmaceutical Journal URI: 20008299

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Patient Care in Community Practice

    Patient Care in Community Practice

    Patient Care in Community Practice is a unique, practical guide for healthcare professionals or carers. Covers a range of non-medicinal products suitable for use at home.

    £22.00Buy now
  • Clinical Pharmacokinetics

    Clinical Pharmacokinetics

    A practical guide to the use of pharmacokinetic principles in clinical practice. Includes case studies with questions and answers.

    £33.00Buy now
  • Strategic Medicines Management

    Strategic Medicines Management

    A practical guide to influencing the availability of medicines, and policies of their use. Focuses on the strategic elements of medicines management.

    £33.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Rate
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.